Long-term classification stability and treatment patterns of inflammatory bowel disease unclassified: a longitudinal observational study Authors: Mario Andrea Latorre, Michael Rennie, Konstantina Rosiou, Marco Vincenzo Lenti, Christian Philipp Selinger Published: 2026 ABSTRACT AbstractObjectiveIn patients presenting with inflammatory bowel disease (IBD), it may not be possible to diagnose ulcerative colitis (UC) or Crohn’s disease (CD) and a classification of IBD Unclassified (IBD-U) is applied. We aim to describe the long-term natural history and treatment patterns in IBD-U.MethodsThis analysis was based on the Leeds IBD Steroid Study, a large retrospective study conducted at Leeds Teaching Hospitals (a UK-based tertiary IBD unit) that included all adult patients with an established diagnosis of IBD who had contact with the service between January 2016 and December 2017 and where access to primary care records were linked to hospital electronic records. Patients with IBD-U were analysed retrospectively. Baseline demographics and treatment patterns of patients with IBD-U were compared with UC and CD. Longitudinal follow-up occurred until 2025 to determine stability of IBD-U diagnosis.ResultsOf 153 patients with IBD-U, 52% were male; the mean age was 46.6 years, and the mean disease duration was 13.1 years. Patients with IBD-U were less likely to receive mesalazine (85%) compared with UC (92%, p=0.0058) but more likely than patients with CD (44%, p<0.0001). Biologics were more often used for IBD-U (21%) than UC (9.5%, p<0.0001) but less often than CD (51%, p<0.0001). Steroid use and use of healthcare resources were higher in IBD-U than in UC and CD. 12 patients (7.8%) were reclassified as UC, 6 patients (3.9%) were reclassified as CD and 135 patients (88.2%) remained classified as IBD-U at the end of follow-up.ConclusionIBD-U remains largely a stable diagnosis over long-term follow-up. Patients with IBD-U exhibit distinct therapeutic patterns and increased healthcare utilisation compared with UC and CD. These findings underscore the clinical relevance of IBD-U as a persistent phenotype and highlight the need to optimise treatment decisions and reduce the burden associated with diagnostic uncertainty. WHAT IS ALREADY KNOWN ON THIS TOPIC WHAT THIS STUDY ADDS We demonstrate in a prevalent cohort that the majority of patients remain diagnosed as IBD-U and treatment patterns differ from ulcerative colitis and Crohn’s disease. We demonstrate in a prevalent cohort that the majority of patients remain diagnosed as IBD-U and treatment patterns differ from ulcerative colitis and Crohn’s disease. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Clinicians should view IBD-U as an independent diagnostic phenotype and avoid delays in initiating effective therapies. Clinicians should view IBD-U as an independent diagnostic phenotype and avoid delays in initiating effective therapies. Introduction Inflammatory bowel disease (IBD) includes ulcerative colitis (UC) and Crohn’s disease (CD), two chronic immune-mediated conditions causing recurrent inflammation of the gastrointestinal tract. UC usually presents with continuous inflammation of the colonic mucosa, starting in the rectum and extending proximally, whereas CD can affect any part of the gastrointestinal tract and is characterised by patchy, transmural inflammation that can lead to strictures or fistulas.1 2 In most cases, clinical, endoscopic, radiologic and histologic features allow clinicians to clearly distinguish UC from CD. However, in a minority of patients presenting with colitis, it is not always possible to firmly make a diagnosis of UC or CD.3 4 To provide a unique diagnostic label for such cases, the term IBD Unclassified (IBD-U) should be used. European Crohns and Colitis Organisation and British Society of Gastroenterology guidelines define IBD-U as a chronic colitis in which the available data do not allow a clear diagnosis of UC or CD.35 The term is specifically used in non-surgical patients and differs from ‘indeterminate colitis’, which refers to colectomy specimens with overlapping features. Diagnostic uncertainty may occur for several reasons, including fulminant presentations, rectal sparing, segmental or patchy colitis, limited biopsies, equivocal histopathological features or treatment-modified features.5 The prevalence of IBD-U varies between 5% and 15% of total IBD cohorts depending on population and diagnostic approach.6 7 IBD-U is a heterogeneous condition and may represent early UC/CD or a stable phenotype in a subgroup of patients. Only a small number of cohort studies have focused specifically on the evaluation of the evolution of IBD-U. In the European population-based Epi-IBD cohort, 25% of patients were reclassified within 5 years, most often as UC (71%). The median time to reclassification was 6 months. The overall disease course was generally mild, with hospitalisation in 14% and surgery in 7%.8 10-year follow-up data from the same cohort confirmed a cumulative reclassification rate of 32% at 10 years.9 A recent Chinese multicentre study reported higher frequencies of rectal sparing (60%), segmental colitis (70%) and gastrointestinal bleeding (32%) compared with UC and CD.10 After almost 7 years of follow-up, 24% were reclassified as UC and 22% as CD.10 Haemorrhage predicted reclassification to CD, while hypoalbuminaemia predicted reclassification to UC.10 These results confirm that although reclassification is common, a relevant proportion of patients remain IBD-U long term. The limited available evidence suggests that treatment strategies for IBD-U vary across regions. In the Epi-IBD cohort, treatment resembled UC therapy, with frequent use of 5-aminosalicylates (5-ASA) (96%) and corticosteroids (49%) and limited use of immunomodulators or biologics,8 whereas Asian cohorts reported more intensive medical therapy and higher need for surgery in keeping with a more CD-like clinical picture over time.10 Some of the differences could be explained by differences in the criteria applied in routine clinical practice to reach a label of IBD-U. We hypothesise that in addition, diagnostic uncertainty could delay treatment escalation, leading to prolonged corticosteroid exposure. Excess steroid use is associated with infections, hospitalisations and increased healthcare utilisation, as demonstrated in the Leeds IBD Steroid Study.11 Recognising disease behaviour earlier could therefore help improve disease control and avoid potential adverse outcomes caused by steroids. Despite available data, important gaps remain regarding long-term outcomes, diagnostic evolution and real-world treatment patterns in IBD-U. We therefore aim to describe the clinical history of a prevalent cohort of patients with IBD-U and their treatment patterns. The Leeds IBD Steroid Study provides a well-defined cohort in which reclassification rates, treatment trajectories and healthcare utilisation can be evaluated over an extended follow-up. Methods Cohort composition and baseline data This analysis was based on the Leeds IBD Steroid Study, a large retrospective study conducted at Leeds Teaching Hospitals (a UK-based tertiary IBD unit) that included all adult patients with an established diagnosis of IBD who had contact with the Leeds IBD service between January 2016 and December 2017 and where access to primary care records were linked to hospital electronic records.11 Clinical, endoscopic, histological, treatment-related, healthcare resource use (ie, IBD clinic appointments, hospital admissions, number of endoscopies and cross-sectional scans) and follow-up information were extracted from the electronic patient record, providing a comprehensive dataset. Medication use was extracted from primary care and hospital records therefore capturing all medication prescriptions including primary prescriptions for steroids. Of a total of 2246 patients included in the original cohort, 1051 patients had UC (47%), 1042 patients had CD (46%) and 153 patients were diagnosed with IBD-U (7%). The diagnosis of IBD-U in 153 patients was assigned when the available clinical, endoscopic and histological information did not allow clear distinction between UC and CD at the time of diagnosis and has remained so until last follow-up at study entry. The study dataset included detailed information on demographics (age and sex) and clinical features including disease phenotype and distribution, prior and current medications (5-ASA, thiopurines, biologics and methotrexate), endoscopic findings, histological reports, radiological investigations, IBD clinic attendance, GP contacts and hospital admissions, corticosteroid prescribing patterns and safety outcomes (admission and infection). Data and analytical methods We performed a comparative analysis of IBD-U versus UC and versus CD to determine baseline factors at study entry associated with IBD-U diagnosis. Furthermore, we examined treatment patterns and healthcare usage for IBD-U versus UC and versus CD to explore potential under or overtreatment of IBD-U. Steroid excess was defined as >1 course of oral steroids over a 12-month period. For our analysis, we used longitudinal follow-up and retrospective data extraction to examine whether the diagnosis of IBD-U remained consistent over time in the prevalent cohort. All patients included in the IBD-U cohort were followed up longitudinally through routine clinical care at Leeds Teaching Hospitals, UK, until 31 July 2025. Follow-up included outpatient consultations, endoscopic procedures, radiological imaging (magnetic resonance enterography (MRE) or CT as clinically indicated), histological reports from biopsies and treatment history. For each patient, we reviewed the complete electronic record from study inclusion until their most recent clinical consultation. The primary endpoint of the longitudinal analysis was a change in diagnosis to UC or CD. We also recorded the time from study inclusion to any change in diagnosis, and the clinical, endoscopic, histological or radiological features that justified the new classification or whether the patient remained classified as IBD-U throughout the follow-up period. For this study, a change in diagnosis was defined as a clear reclassification from the initial diagnosis of IBD-U to UC or CD during follow-up. Reclassification required documented evidence from clinical, endoscopic, radiological and/or histological assessment, as recorded by the treating IBD specialist. Reclassification to UC Patients were reclassified as UC if they developed features consistent with a typical UC phenotype, including: Continuous colitis with rectal involvement. Continuous colitis with rectal involvement. Absence of small bowel disease on endoscopy or imaging. Absence of small bowel disease on endoscopy or imaging. Lack of transmural or fistulising complications. Lack of transmural or fistulising complications. Histological findings consistent with UC (eg, diffuse mucosal chronic inflammation, crypt architectural distortion and basal plasmacytosis). Histological findings consistent with UC (eg, diffuse mucosal chronic inflammation, crypt architectural distortion and basal plasmacytosis). A clinician-documented diagnosis of UC in the electronic patient record. A clinician-documented diagnosis of UC in the electronic patient record. Reclassification to CD Diagnosis was changed to CD if patients exhibited one or more of the following: Segmental or patchy colitis in combination with at least one other factor. Segmental or patchy colitis in combination with at least one other factor. Endoscopic or radiological evidence of terminal ileal involvement. Endoscopic or radiological evidence of terminal ileal involvement. Presence of transmural complications (fistula, abscess or stricturing disease). Presence of transmural complications (fistula, abscess or stricturing disease). Granulomas on histology not due to crypt rupture. Granulomas on histology not due to crypt rupture. Small bowel inflammation on MRE/CT or endoscopy. Small bowel inflammation on MRE/CT or endoscopy. A clinician-documented diagnosis of CD. A clinician-documented diagnosis of CD. Patients remaining IBD-U Patients were classified as remaining IBD-U if: No diagnostic features emerged that clearly supported UC or CD. No diagnostic features emerged that clearly supported UC or CD. Findings remained ambiguous or overlapping. Findings remained ambiguous or overlapping. All available follow-up data were insufficient to support reclassification. All available follow-up data were insufficient to support reclassification. Statistical analysis Descriptive statistics are reported as median or proportions. Categorical data were compared between groups using the χ2 test, whereas the independent samples t-test or Mann-Whitney U test was used for continuous variables. Differences were considered statistically significant if p<0.05. IBM SPSS V.25 was used for statistical analysis. Results Of the 153 included patients with IBD-U, 52% were male; the mean age was 46.6 years at study inclusion. Mean disease duration in 2018 was 13.1 years. There were no differences in sex, age and disease duration between IBD-U cases compared with UC or CD (table 1). Table 1Baseline characteristics of IBD-U cohort compared with UC and CDIBD-UUCP valueCDP valueMale79 (52%)517 (49%)0.55472 (46%)0.14Female74 (48%)534 (51%)570 (54%)Mean age (years)46.648.50.2146.10.78Mean disease duration (years)13.115.10.8311.60.21CD, Crohn’s disease; IBD-U, Inflammatory Bowel Disease Unclassified; UC, ulcerative colitis. Baseline characteristics of IBD-U cohort compared with UC and CD CD, Crohn’s disease; IBD-U, Inflammatory Bowel Disease Unclassified; UC, ulcerative colitis. Treatment patterns We identified significant differences in the medical treatment patterns of IBD-U compared with UC and CD. Patients with IBD-U were less likely to ever receive mesalazine (85%) treatment compared with UC (92%, p=0.0058; table 2), but far more likely than patients with CD (44%, p<0.0001). Thiopurine treatment patterns did not differ between IBD-U and UC, but more patients with CD received thiopurines (67% vs 39%, p=0.0026). Patients with IBD-U were more likely to ever receive infliximab (13%) compared with UC (7%, p=0.0094), but less likely compared with CD (30%, p<0.0001). Adalimumab treatment patterns did not statistically differ between IBD-U and UC, but more patients with CD received adalimumab (21% vs 5%, p<0.0001). We did not observe any differences in vedolizumab treatment though numbers were low for any exposure overall. Table 2Ever exposure to IBD maintenance medication according to IBD diagnosisIBD-UUCP valueCDP valueCohort size1531051n/a1042n/aMesalazine130 (85%)965 (92%)0.0058*454 (44%)<0.0001*Thiopurines59 (39%)370 (35%)0.41700 (67%)0.0026*Infliximab20 (13%)74 (7%)0.0094*311 (30%)<0.0001*Adalimumab8 (5%)26 (2.5%)0.055215 (21%)<0.0001*Vedolizumab0 (0%)10 (1%)0.2312 (1%)0.18*Statistical significance.CD, Crohn’s disease; IBD-U, Inflammatory Bowel Disease Unclassified; UC, ulcerative colitis. Ever exposure to IBD maintenance medication according to IBD diagnosis Statistical significance. CD, Crohn’s disease; IBD-U, Inflammatory Bowel Disease Unclassified; UC, ulcerative colitis. The treatment of disease flares with oral steroids differed between patients with IBD-U and UC or CD. Significantly more patients with IBD-U were exposed to any steroids (42%) compared with UC (33%, p=0.0298) and CD (32%, p=0.0166, table 3). While steroid excess and avoidable steroid excess were numerically more common in IBD-U, the differences were not statistically significant. Table 3Exposure to steroid treatment during the original 2016–2018 periodIBD-UUCP valueCDP valueCohort size1531051n/a1042n/aAny steroid exposure64 (42%)346 (33%)0.0298*334 (32%)0.0166*Steroid excess27 (18%)153 (15%)0.37144 (14%)0.21Avoidable steroid excess21 (14%)110 (10%)0.51106 (10%)0.41*Statistical significance.CD, Crohn’s disease; IBD-U, Inflammatory Bowel Disease Unclassified; UC, ulcerative colitis. Exposure to steroid treatment during the original 2016–2018 period Statistical significance. CD, Crohn’s disease; IBD-U, Inflammatory Bowel Disease Unclassified; UC, ulcerative colitis. Healthcare usage We analysed healthcare usage during the 2016–2018 period. The mean number of clinic appointments for IBD-U (3.8 over 2 years) was similar to that of CD (4.1, p=0.25), but significantly higher than for patients with UC (3.1, p=0.017, table 4). Helpline contacts were similar for IBD-U compared with UC and CD. Patients with IBD-U were less likely to require hospital admission (12%) compared with CD (16%, p=0.0065) but there was no difference compared with UC. We detected significant differences in the pattern of IBD investigations. The mean number of MRI scans was higher for CD compared with IBD-U (0.39 vs 0.1, p<0.0001), but patients with UC required fewer MRI scans (0.04, p<0.0001) compared with IBD-U. The number of endoscopic investigations also differed by disease. Colonoscopy was used more frequently in IBD-U (0.24 per patient) compared with UC (0.15 per patient, p=0.013) and sigmoidoscopy was used more frequently for IBD-U than for CD (0.27 vs 0.1 per patient, p<0.0001). Table 4Healthcare usage during the original 2016–2018 periodIBD-UUCP valueCDP valueCohort size1531051n/a1042n/aIBD clinic mean appointments per patient3.83.10.017*4.10.25IBD helpline contacts mean appointments per patient1.20.90.110.910.13Hospital admission (yes/no)19 (12%)122 (12%)0.17170 (16%)0.0065*Lower gastrointestinal endoscopy (other than surveillance) Colonoscopy mean per patient0.240.150.013*0.290.25 Sigmoidoscopy mean per patient0.270.350.120.10<0.0001*Cross-sectional imaging CT scan mean per patient0.100.100.850.250.003* MRI mean per patient0.100.04<0.0001*0.39<0.0001**Statistical significance.CD, Crohn’s disease; IBD-U, Inflammatory Bowel Disease Unclassified; UC, ulcerative colitis. Healthcare usage during the original 2016–2018 period Statistical significance. CD, Crohn’s disease; IBD-U, Inflammatory Bowel Disease Unclassified; UC, ulcerative colitis. Natural history of IBD-U Patients from the IBD-U cohort were followed up longitudinally until 31 July 2025 to allow for extended follow-up beyond the original study period. During the follow-up period, 14 patients (9.2%) died (from causes not directly related to IBD). For these patients, longitudinal analyses were censored at the date of death or the date of loss to follow-up. The remaining patients continued active follow-up in the IBD service. At the end of follow-up, the cohort demonstrated heterogeneous diagnostic trajectories, with a small proportion of patients undergoing diagnostic reclassification to UC or CD. Of the 153 patients included in the cohort, 12 patients (7.8%) were reclassified as UC, 6 patients (3.9%) were reclassified as CD and 135 patients (88.2%) remained classified as IBD-U at the end of follow-up. Thus, the overall rate of diagnostic reclassification was 11.8%, with reclassification to UC being more frequent than to CD. Where diagnostic reclassification occurred, in most cases, the change in diagnosis was observed within the first few years of follow-up, following repeat endoscopic assessment, cross-sectional imaging or multidisciplinary review. However, late diagnostic reclassification was also observed, with several patients being reclassified more than 5 years after the initial IBD-U diagnosis. These later changes were typically driven by the emergence of CD-defining features on imaging or by the accumulation of histological features on repeated biopsies. Review of longitudinal clinical data indicated that diagnostic change was most commonly associated with the appearance of new disease-defining features during follow-up, including the development of clear endoscopic patterns suggestive of UC, such as continuous colonic involvement and a stable disease pattern with rectal involvement only, or the identification of features suggestive of CD, including ileal involvement or segmental disease distribution, evolution of histological findings towards patterns more clearly compatible with UC or CD, or radiological evidence emerging over time, particularly cross-sectional imaging supporting transmural disease in patients later reclassified as CD. Reclassification to UC Reclassification to UC was driven predominantly by convincing histological evidence. In all 12 cases, repeat endoscopic biopsies demonstrated features consistent with UC, including chronic architectural distortion, basal plasmacytosis and a continuous distal inflammatory pattern. In several cases, reclassification to UC followed histopathology review at multidisciplinary team meetings. No patients reclassified to UC developed small bowel involvement, perianal disease or other CD-qualifying features during follow-up. Reclassification to CD Among the six patients reclassified to CD, the reasons for diagnostic change were more heterogeneous. Four patients developed evidence of small bowel involvement, identified through cross-sectional imaging (CT or MRI), including ileal inflammation or stricturing disease. One patient was reclassified following the development of complex perianal fistulising disease, and one patient based on histological findings consistent with CD on repeat biopsies. In these cases, the emergence of CD-specific features occurred several years after the initial IBD-U diagnosis. Stability of IBD-U diagnosis The majority of patients (88.2%) remained classified as IBD-U throughout prolonged follow-up. These patients did not develop clear diagnostic features of UC or CD despite repeated clinical assessments, endoscopic evaluations and imaging where indicated. Discussion In this large cohort, we provide a comprehensive description of the long-term clinical course of patients diagnosed with IBD-U focusing on diagnostic stability, treatment patterns and healthcare utilisation. Our findings highlight that IBD-U, while representing a dynamic diagnostic category in principle,4 remains stable over time in the majority of patients. In this prevalent cohort with a mean disease duration over 10 years, only a minority of patients underwent diagnostic reclassification to UC or CD after a prolonged follow-up. Our findings suggest the concept that IBD-U is not only a transient label but may represent a clinical phenotype often used as a long-term classification in routine practice. One of the key findings of this study is the relatively high diagnostic stability observed in patients with IBD-U. As our study examines a prevalence cohort, it is feasible that early reclassification from IBD-U to UC or CD has already occurred. For example, in the Epi-IBD inception cohort, reclassification occurred after a median of only 6 months in 25% of initial IBD-U diagnoses,8 possibly indicating a very early IBD diagnosis. This aligns with our finding that in most patients reclassification occurs early and late reclassification is the exception.8 When rediagnosis occurred, reclassification was more commonly towards UC than CD. This pattern is again consistent with previous studies, including the Epi-IBD cohort and the study by Shao et al.8 10 We identified significant differences in treatment patterns for patients with IBD-U. Our analysis of treatment patterns during the period between 2016 and 2018 showed that the treatment pattern followed neither the treatment pattern for UC nor that for CD closely. Compared with UC, there was less use of mesalazine but higher use of biologics. In contrast, patients with IBD-U were more often treated with mesalazine and less often treated with thiopurines and biologics compared with CD. This treatment pattern of biologics use could reflect a more aggressive disease course or clinicians’ attitude towards IBD-U. Our study data are from 2016 to 2018, when biologic use for UC was still considerably lower than seen in current practice.11 12 It is conceivable that with the degree of uncertainty that may be perceived with an IBD-U diagnosis, clinicians could be inclined to opt for biologics earlier than when treating UC. The rate of biologic use in our cohort (21%) is higher than seen in the Epi-IBD cohort (10%).8 The Epi-IBD cohort reports a slightly earlier treatment period and in general biologic use in IBD increased considerably during the period of 2010–2020.13 Steroid use can reflect quality of care in IBD, and measuring steroid use has been established as a Key Performance Indicator in the UK.1416 We observed more frequent steroid exposure in IBD-U compared with UC and CD. Steroid excess in IBD-U occurred in 18% of patients in the study cohort. Reassuringly, however, steroid use meeting criteria for excessive use (>1 course per year or >3 months in a year) or inappropriate steroid excess was not increased compared with UC or CD. The higher use of steroids for IBD-U again suggests a degree of indecision in treating IBD-U and perhaps a slight reluctance to start advanced therapies in some cases. Our findings support the use of advanced therapies to reduce steroid exposure and suggest that diagnostic uncertainty plays a significant role in therapeutic decision-making, delaying the introduction of steroid-sparing therapies. This highlights the clinical challenge of balancing treatment intensity against diagnostic confidence, particularly in patients without well-defined phenotypes. Patients with IBD-U exhibited higher healthcare usage compared with UC, including increased outpatient visits and endoscopic investigations. This increased burden likely reflects a combination of factors. Diagnostic uncertainty often brings repeated assessments, endoscopic procedures and imaging studies to evaluate disease evolution and reassess phenotype. In addition, IBD-U may represent a group with more complex and aggressive disease presentations, requiring closer clinical surveillance. While healthcare usage in IBD-U remained lower than that observed in CD, it was consistently higher than in UC, suggesting that IBD-U occupies an intermediate position not only in terms of treatment patterns but also in healthcare burden. These findings reinforce the notion that IBD-U is associated with clinical and healthcare burden, rather than being a purely semantic diagnosis. Our results raise the question of whether earlier phenotypic reclassification in IBD-U could improve clinical outcomes and reduce healthcare burden. Earlier diagnostic reclassification may facilitate more targeted therapy and reduce steroid exposure. However, it is important to consider that in many patients, diagnostic uncertainty persists despite comprehensive investigation and forced reclassification may lead to inappropriate treatment choices. Therefore, while efforts to improve early phenotypic classification are desirable, IBD-U should also be recognised as a diagnosis when uncertainty remains despite adequate evaluation. In this context, structured follow-up and regular reassessment, rather than premature diagnostic closure, may represent the most appropriate strategy. The strengths of this study include the size of the cohort, which is larger than previously reported IBD-U cohorts, and the long-term follow-up within a single tertiary referral centre. Importantly, our cohort represents a prevalent population rather than an inception cohort, providing insights into the real-world evolution of IBD-U over time. We are, however, unable to report on early diagnostic reclassification due to the nature of our cohort. The availability of detailed clinical, endoscopic, histological and treatment data allowed a comprehensive assessment of diagnostic trajectories and healthcare utilisation. We did not capture data on surgical outcomes. As a single-centre study, our findings are of course influenced by the approach of our clinicians and may not necessarily apply to other centres or within different healthcare settings. While prospective multicentre studies are desirable, very few studies on the natural history of IBD-U have been reported, so we believe that our study provides an important addition to the literature. Conclusion IBD-U is a dynamic but frequently stable diagnosis over long-term follow-up. A minority of patients are reclassified to UC or CD, often early in the disease course. The majority of patients remain diagnosed as IBD-U, exhibiting distinct therapeutic patterns and increased healthcare utilisation compared with UC. These findings underscore the clinical relevance of IBD-U as a persistent phenotype and highlight the need for ongoing efforts to refine diagnostic strategies, optimise treatment decisions and reduce the burden associated with diagnostic uncertainty.